Nike's Turnaround Is Still Falling — Revenue Down, Margins Down, China Down 20%

Nike is the most valuable name in sport, an icon so dominant that for a generation its swoosh was a synonym for athletic apparel itself. After a punishing stretch, the market has decided the worst is behind it — that the return of a veteran leader, a renewed focus on product and sport, and a cleanup of bloated inventory mean the turnaround is underway and the bottom is in. The stock trades on that hope. But the most recent quarter, the third of its fiscal 2026, describes a company that is still going down, not yet coming back. Revenue fell 3% on a currency-neutral basis. Gross margin compressed 130 basis points. Greater China — once one of Nike's richest profit pools — is deteriorating so badly that management warned of a roughly 20% decline ahead. And the company's own words about its recovery were that it is "taking longer than anticipated." A turnaround and a rebound are not the same thing: one is the hard, multi-year work of repair, the other is the snap-back the market is pricing. This is a piece about the distance between them, and about why Nike's recovery is, for now, still a rebuild with the numbers pointing the wrong way.

---

Begin with the genuine strength, because Nike remains a colossus and counting it out would be foolish. It is the largest athletic brand in the world, with unmatched marketing power, a fortress balance sheet, deep relationships with athletes and leagues, and a product-innovation capability that, when focused, has repeatedly defined the category. Its third-quarter revenue of $11.3 billion is still an enormous business, and the company has the financial strength to fund a long recovery without strain. The return of a seasoned leader who knows the company intimately, and the strategic refocus on sport, product, and wholesale partnership, are widely — and rightly — regarded as the correct medicine. This essay does not argue that Nike is broken beyond repair; it is not.

The argument is narrower: that the market has begun to price the recovery as if it were largely accomplished, while the financial results show a company whose revenue, margins, and most important international market are all still moving in the wrong direction, and whose own management describes the repair as slower than hoped. So this essay examines the gap between a turnaround and a rebound, the self-inflicted nature of Nike's wounds, the structural deterioration in China, the margin pressure, and the competitors who took share while Nike stumbled.

A turnaround is not a rebound

Start with the distinction the stock is glossing over. A rebound is a snap-back: the troubles were cyclical or temporary, the business was fundamentally fine, and once the transient pressure passes the numbers spring back. A turnaround is something harder and slower: the business has real, structural problems that must be fixed through sustained effort over many quarters, with the results often getting worse before they get better as the company takes its medicine. The market frequently confuses the two, bidding a stock up on the announcement of a turnaround as though it were the arrival of a rebound — and Nike's recent strength has the flavor of exactly that confusion.

The evidence says Nike is in a turnaround, not a rebound. Revenue declined 3% on a currency-neutral basis in the quarter — not flat, not inflecting upward, but still falling. Gross margin fell 130 basis points. Guidance for the following quarter called for revenue down another 2% to 4%. And management, asked about the pace of recovery, conceded it was taking longer than anticipated. None of that is the signature of a rebound; all of it is the signature of a company in the middle of a hard repair, still absorbing the costs of fixing itself. The work may well succeed — Nike has the resources and the brand to pull it off — but a buyer paying rebound prices for a turnaround that is still, by every current metric, deteriorating is paying for an outcome that has not arrived and that the company itself says is further off than expected.

The wounds were self-inflicted, which makes them slower to heal

It matters a great deal that Nike's troubles were largely self-inflicted, because self-inflicted wounds take specific, deliberate work to undo. In the years before this turnaround, Nike made two consequential strategic errors. First, it over-pivoted to direct-to-consumer selling — pushing customers to its own apps and stores while pulling back from the wholesale partners, the retailers and specialty shops, that had long put Nike product in front of shoppers. That retreat ceded shelf space and visibility to competitors precisely when those competitors were surging. Second, it under-invested in genuine product innovation, leaning on tired franchises and retro re-releases rather than the new performance and lifestyle product that built the brand, leaving its lineup stale.

The turnaround now under way is, in essence, the reversal of those errors: re-engaging the wholesale partners Nike alienated, and rebuilding the innovation pipeline it neglected. Both are the right moves. But both are slow. Winning back a wholesale partner's trust and shelf space after you walked away from them is a multi-season negotiation, not a press release; rebuilding a product-innovation pipeline from concept to shelf takes years, because the shoes selling next season were designed seasons ago. This is why the recovery is taking longer than anticipated — not because management is failing, but because undoing a strategic error of this magnitude is inherently a multi-year project, and the market's hope for a quick rebound collides with the structural reality that repairing self-inflicted damage cannot be rushed. The medicine is correct; the cure is measured in years, and the stock is priced closer to quarters. It is worth stressing that this is not a criticism of the strategy — re-engaging wholesale and rebuilding innovation are exactly what Nike should be doing — but a point about time: a company can be doing everything right and still face several more years of soft results while the right things compound, and a valuation that has run ahead to the finish line has to live through the middle distance first.

China is not just weak; it is structurally harder

The single most alarming line in the quarter was Greater China, and it deserves particular attention because China was, for years, one of Nike's most profitable growth engines. Now management is warning of a decline on the order of 20% in its key China market in the current quarter, and projecting that China sales will keep falling. A 20%-magnitude decline in a major profit pool is not a rounding error; it is the erosion of a pillar, and it lands on a market that historically carried some of Nike's highest margins, so the profit impact runs heavier than the revenue figure alone suggests.

What makes it more worrying than a simple cyclical dip is that the pressures are substantially structural. Domestic Chinese athletic brands — Anta, Li-Ning, and others — have grown enormously in capability and consumer appeal, backed by nationalist sentiment that increasingly favors local brands over Western ones, and by a Chinese consumer who has turned more cautious amid a weak economy and a property slump. Each of those forces is durable, not transient: the rise of credible domestic competitors does not reverse, nationalist consumer preference does not fade on Nike's schedule, and the Chinese consumer's caution reflects deep economic conditions outside Nike's control. So the China weakness is not the kind of thing a better product cycle in North America fixes; it is a structural reweighting of one of Nike's most important markets away from it, and the turnaround thesis has to account for the possibility that the China profit pool simply does not come back to what it was. A recovery built on North America while China keeps falling is a recovery with a hole in it.

The margin is compressing from two directions

Profitability tells its own cautionary story. Gross margin fell 130 basis points to 40.2% in the quarter, pressured notably by higher tariffs in North America, and the inventory cleanup at the heart of the turnaround implies more discounting to come. This is a two-sided squeeze. On one side, the cost of goods is rising — tariffs on imported product hit a company that manufactures overseas directly in the margin. On the other side, the turnaround itself requires clearing excess and stale inventory, which is done through markdowns and promotions that lower realized prices. Rising costs and falling prices at the same time is precisely the recipe for margin compression, and it is visible in the numbers.

The bull case holds that this is temporary — that once the old inventory is cleared and the fresh, innovative, full-price product arrives, pricing power and margins recover. That is plausible and may well happen. But it is a forward-looking hope resting on the success of a product pipeline that is still being rebuilt, and in the meantime the margins are going down, not up. A premium for a consumer brand is, in large part, a bet on its pricing power and margin trajectory, and Nike's margins are currently moving the wrong way under pressures — tariffs and clearance — that are real and present, against a recovery in pricing power that is promised and future. The order of operations matters: the pain is now and certain, the relief is later and contingent.

The competitors who walked through the open door

While Nike stumbled, the field did not wait. On Holding, with its distinctive running franchise, and Hoka, under Deckers, with its maximalist performance shoes, grew rapidly into exactly the performance-running space Nike had long dominated. New Balance staged a remarkable resurgence in both performance and lifestyle. Adidas reignited demand with retro franchises like the Samba and Gazelle. Each of these gains came, in part, from the shelf space, the cultural momentum, and the customer attention that Nike vacated when it retreated to direct-to-consumer and let its product pipeline go stale. Brand momentum in athletic footwear is partly a cultural phenomenon, and culture, once it shifts toward a challenger, is hard and slow to shift back.

This is why the competitive backdrop makes the turnaround harder than a simple internal fix would be. Nike is not merely reigniting its own engine in a vacuum; it is trying to win back attention and shelf space from competitors who are now established, capable, and culturally relevant in ways they were not a few years ago. Reclaiming a runner who switched to On, or a teenager who now wants Sambas, is harder than keeping them would have been. Nike's scale and marketing power give it a real chance — no challenger approaches its resources — but the existence of a credible, energized competitive set means the turnaround is a contested fight, not an uncontested recovery, and the market's pricing seems to assume the field will politely cede the ground back. It will not.

What the bulls genuinely get right

In fairness, the bull case is real and Nike's eventual recovery is a reasonable expectation — the debate is timing and price, not whether the brand survives. Nike is the most powerful athletic brand on earth, with scale, marketing firepower, athlete and league relationships, and a balance sheet that let it fund a long recovery comfortably. The leadership change brought back a respected veteran who understands the company and is making demonstrably correct moves: cleaning up inventory, re-engaging wholesale, and refocusing on sport and innovation. These are exactly the right actions, and the fact that they are painful in the near term is evidence the company is taking its medicine rather than papering over the problems. Q4 guidance even points to modest growth in North America, a tentative sign that the largest market may be stabilizing. Iconic consumer brands have come back from worse — Nike itself has navigated past stumbles — and a brand this strong, once its product engine reignites, can recapture momentum quickly. For investors who believe the turnaround is genuinely working and simply early, the current weakness is the buying opportunity before the inflection.

The honest synthesis is that Nike is a great brand making the right moves in a turnaround that is real, correct, and slower than hoped — and the bull is right that the brand, the balance sheet, the leadership, and the North America stabilization are genuine. The skeptic notes that revenue is still falling, margins are still compressing, China is in structural decline, the wounds were self-inflicted and therefore slow to heal, energized competitors hold ground Nike must recapture, and management itself says the recovery is taking longer than anticipated — so the stock, priced for a rebound, is underwriting an inflection the numbers have not yet begun to show.

The inventory that will not quite clear

There is a quieter number that captures the slow grind of the repair: inventory. As of the end of February, Nike's inventories stood at $7.5 billion, essentially flat versus the prior fiscal year-end, with the company noting that the dollar figure reflected an increase in units offset by product mix. For a turnaround whose central near-term task is to clear excess and stale product so that fresh, full-price innovation can take its place, flat inventory — with units actually rising — is not the picture of a cleanup nearing completion. It is the picture of a cleanup still in progress, with a great deal of product still to move through markdowns before the shelves are ready for the new lineup that is supposed to restore pricing power.

This matters because the sequence of a successful turnaround is specific: clear the old inventory, which depresses margins through discounting; then introduce the new, innovative, full-price product, which restores them. Nike is still in the first phase, the painful one, and the flat-to-rising inventory says that phase is not yet behind it. Until the channel is genuinely clean, the margin pressure from clearance continues, the fresh product cannot get full shelf space, and the inflection the stock is pricing cannot begin. The inventory line is unglamorous, but it is an honest gauge of where the company actually is in the repair — and it says, like the revenue and the margin and the China warning and management's own words, that the work is still being done, not finished.

What the price is assuming

Pull it to the level of the valuation, because that is where the disagreement resolves. A consumer-brand stock that has rallied on turnaround hope embeds an assumption that the inflection is near — that revenue stops falling soon, that margins trough and recover, that China stabilizes, and that the product pipeline reignites demand on a foreseeable timeline. Each of those is possible; none of them is yet visible in the results, and several face structural rather than cyclical headwinds. The risk is not that Nike fails — it very likely recovers eventually — but that the recovery takes meaningfully longer than the price assumes, with more quarters of falling revenue, compressed margins, and Chinese decline before the inflection arrives, during which a stock priced for imminent rebound has room to disappoint.

The deeper point is that turnarounds at great brands are usually right in direction and wrong in speed: the strategy works, but it works over years, and the market's patience is measured in quarters. Nike will probably be a fine business again. The question the price is answering too confidently is when — and the company's own admission that the repair is taking longer than anticipated is the most honest guide available, more honest than the hope embedded in the stock. The bottom may be near; it is not, on the evidence of this quarter, here.

The kicker

Nike is not a broken company, and this is not a prediction of its decline — it is the most powerful brand in sport, it has the resources to fund a long recovery, and its leadership is making the right moves. But the market has begun to treat a turnaround as though it were a rebound, pricing the snap-back while the actual numbers — revenue down, margins down, China down twenty percent, recovery slower than hoped — all still point the wrong way. The medicine is correct and the patient is strong, but the cure is measured in years, the wounds were self-inflicted and heal slowly, the competitors who took the ground are not giving it back, and China may not return to what it was. Nike will likely come back. The stock is priced as though it already has.

The most iconic brand in sport is doing the right things and saying the honest one — that the repair is taking longer than anyone wanted — while its revenue keeps slipping, its margins keep thinning, and a quarter of its old Chinese fortune walks out the door toward homegrown rivals; the market, impatient for the comeback story it loves, has chosen to hear the word turnaround as the word rebound, and the gap between those two words, measured in years of falling numbers the price has decided to skip past, is exactly where the risk in owning the swoosh today quietly lives.